MoonLake Immunotherapeutics Class A

Stage 4 · Declining · week 6

As of Oct 22, 2026, MoonLake Immunotherapeutics is in Stage 4, the downtrend phase, now in week 6 (since Sep 17, 2026). It closed at $12.34, 44.3% below its 52-week high and below its 200-day average, which is falling.

MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. More about the company

$12.34

+15.87% today

$1.1B · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is MLTX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 15w

S2 16w

S4 13w

S1 19w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 10w → S3 10w → S2 9w → S3 4w → S4 15w → S1 11w → S2 16w → S3 4w → S4 13w → S1 7w → S2 10w → S3 2w → S4 12w → S1 19w → S4 2w → S1 3w → S2 8w → S3 4w → S4 5w current

Total tracked: 165 weeks across 19 stage runs.

MLTX among Biotechnology114th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…114	MLTXMoonLake Immunotherapeutics Class A	Stage 4 · wk 6	79	−4.3%

vs 52W High

-44.3%

$9.46 lo$22.16 hi

44.3% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 6

1w13w26w

Week 6, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-25.6%

200 DMA: $16.59 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

3.83x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-4.3%

-35.1%

-27.1%

YTD

+3.3%

+34.7%

Scan Membership

Breakout Watch

Latest: 2024-10-08

4 appearances in last 60 days. First seen: 2022-04-04.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 6 · Vol 3.83x

2026-10-21S4

Wk 5 · Vol 0.63x

2026-10-20S4

Wk 5 · Vol 0.73x

2026-10-19S4

Wk 5 · Vol 0.54x

2026-10-16S4

Wk 5 · Vol 0.82x

2026-10-15S4

Wk 5 · Vol 0.64x

2026-10-14S4

Wk 4 · Vol 1.07x

2026-10-13S4

Wk 4 · Vol 1.48x

2026-10-12S4

Wk 4 · Vol 0.75x

2026-10-09S4

Wk 4 · Vol 1.26x

2026-10-08S4

Wk 4 · Vol 2.43x

2026-10-07S4

Wk 3 · Vol 0.92x

Moving averages & range

50 DMA

$13.04

200 DMA

$16.59

52W High

$22.16

52W Low

$9.46

5D Low

$9.55

Resistance levels (recent highs)

20d High

$12.34

60d High

$18.99

120d High

$22.16

250d High

$22.16

Next resistance

+53.9%

to 60d High

ROE

-67.5%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 2.4

MoonLake Immunotherapeutics: quick answers

What stage is MoonLake Immunotherapeutics in?

As of Oct 22, 2026, MoonLake Immunotherapeutics (MLTX) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 17, 2026 and is in week 6. What the four stages mean

Is MoonLake Immunotherapeutics in an uptrend?

No. MoonLake Immunotherapeutics is in a Stage 4 downtrend. It trades 25.6% below its 200-day average, which is falling.

How far is MoonLake Immunotherapeutics from its 52-week high?

MoonLake Immunotherapeutics closed at $12.34 on Oct 22, 2026, 44.3% below its 52-week high of $22.16. Its 52-week low is $9.46.

How has MoonLake Immunotherapeutics performed over the past year?

As of Oct 22, 2026, MoonLake Immunotherapeutics is up 34.7% over the past year and up 3.3% so far in 2026.

Which sector and industry is MoonLake Immunotherapeutics in?

MoonLake Immunotherapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.